Known targets — ChEMBL curated mechanism
CSF1RFLT1FLT3FLT4KDRPDGFRAPDGFRB
The experimentally established mechanism targets of Linifanib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 19/20 | 1.00 |
| ▸ | FLT3 known ✓ | P36888 | 16/20 | 1.00 |
| ▸ | CSF1R known ✓ | P07333 | 10/20 | 1.00 |
| ▸ | FLT4 known ✓ | P35916 | 10/20 | 1.00 |
| ▸ | FLT1 known ✓ | P17948 | 9/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 1/20 | 1.00 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 1.00 |
| ▸ | KIT | P10721 | 14/20 | 1.00 |
| ▸ | LYN | P07948 | 7/20 | 1.00 |
| ▸ | SRC | P12931 | 6/20 | 1.00 |
| ▸ | BLK | P51451 | 6/20 | 1.00 |
| ▸ | AURKA | O14965 | 5/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 5/20 | 1.00 |
| ▸ | PLK4 | O00444 | 4/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 4/20 | 1.00 |
| ▸ | MET | P08581 | 4/20 | 1.00 |
| ▸ | PRKACA | P17612 | 4/20 | 1.00 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 1.00 |
| ▸ | CSNK1D | P48730 | 4/20 | 1.00 |
| ▸ | STK3 | Q13188 | 4/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Linifanib SCHEMBL93804 | 1.00 | KDR (1.00) | KDRFLT3KITCSF1RFLT4 | |
| Linifanib SCHEMBL1880038 | 0.99 | KDR (0.98) | KDRFLT3KITCSF1RFLT4 | |
| Linifanib SCHEMBL2239943 | 0.97 | KDR (0.94) | KDRFLT3KITCSF1RFLT4 | |
| SCHEMBL421934 | 0.90 | KDR (0.82) | KDRFLT3KITCSF1RFLT4 | |
| SCHEMBL420765 | 0.90 | KDR (1.00) | KDRFLT3KITCSF1RFLT4 | |
| SCHEMBL1662335 | 0.89 | KDR (0.81) | KDRFLT3KITCSF1RFLT4 | |
| SCHEMBL423705 | 0.89 | KDR (0.80) | KDRFLT3KITCSF1RFLT4 | |
| SCHEMBL1659063 | 0.89 | KDR (0.79) | KDRFLT3KITCSF1RFLT4 | |
| SCHEMBL424019 | 0.89 | KDR (0.79) | KDRFLT3KITCSF1RFLT4 | |
| SCHEMBL6073436 | 0.89 | KDR (0.79) | KDRFLT3KITCSF1RFLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119546749-A | Differentiation of Stem cells into pancreatic endocrine cells | 诺和诺德股份有限公司 | 2025-02-28 | — | — | CN | claimed |
| CN-116139148-B | Medical application of medicine combination | 上海中医药大学附属龙华医院 | 2024-09-06 | — | — | CN | claimed |
| CN-115192564-B | Phenylalanine derivative, pharmaceutical composition and application thereof in tumor treatment | 四川大学华西医院 | 2023-11-17 | — | — | CN | claimed |
| CN-116139148-A | Medical application of medicine combination | 上海中医药大学附属龙华医院 | 2023-05-23 | — | — | CN | claimed |
| CN-115192564-A | Phenylalanine derivative, pharmaceutical composition and application of phenylalanine derivative and pharmaceutical composition in tumor treatment | 四川大学华西医院 | 2022-10-18 | — | — | CN | claimed |
| WO-2026102277-A1 | COMBINATION THERAPIES COMPRISING IKZF2 DEGRADER COMPOUNDS | Plexium, Inc. (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4735120-A2 | CHEMICALLY INDUCED REPROGRAMMING TO REVERSE AGING | President and Fellows of Harvard College (US) | 2026-05-06 | — | — | EP | disclosed |
| WO-2025235298-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING THIAZOLYL DERIVATIVES FOR DEGRADING CERTAIN CYCLIN-DEPENDENT KINASE VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| WO-2025235331-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING PYRAZOLOPYRIMIDINE DERIVATIVES FOR DEGRADING CERTAIN CYCLIN-DEPENDENT KINASE VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| WO-2025235261-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING 2,4,5-SUBSTITUTED PYRIMIDINE DERIVATIVES FOR DEGRADING CERTAIN CYCLIN-DEPENDENT KINASE VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| EP-4615833-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING 2,5-SUBSTITUTED PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | Nikang Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| WO-2025137385-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING PYRIDO[2,3-D]P¥RIMIDIN-7(8H)-ONE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 AND CYCLIN- DEPENDENT KINASE 4 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| CN-114302878-A | Tyrosine kinase non-receptor 1(TNK1) inhibitors and uses thereof | 大日本住友制药肿瘤公司 | 2022-04-08 | — | — | CN | disclosed |
| WO-2022052913-A1 | COMPOSITIONS AND METHODS FOR T CELL ENGINEERING | GRACELL BIOTECHNOLOGIES (SHANGHAI) CO., LTD. (CN) | 2022-03-17 | — | — | WO | disclosed |
| CN-105813655-B | Protein-polymer-drug conjugates | 阿萨纳生物科技有限责任公司 | 2022-03-15 | — | — | CN | disclosed |
| WO-2022043558-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2022-03-03 | — | — | WO | disclosed |
| WO-2022043556-A1 | STABLE RADIOPHARMACEUTICAL COMPOSITION | NOVARTIS AG (CH) | 2022-03-03 | — | — | WO | disclosed |
| WO-2022043557-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2022-03-03 | — | — | WO | disclosed |
| CN-114107424-A | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof | 诺华股份有限公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-114010788-A | Channel modulators | 奥克兰联合服务有限公司 | 2022-02-08 | — | — | CN | disclosed |